{'fraction_non_alphanumeric': 0.024390243902439025, 'fraction_numerical': 0.016260162601626018, 'mean_word_length': 5.291970802919708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Study of immunodepressive and allergic effects of xenon].

Experimental studies on mice showed that after four 30-min and 60-min inhalations of Xe:O2 (80:20) during 2 weeks, weight indexes of the lymphoid organs (spleen and thymus) increased, phagocytic activity did not change, and primary immune response was moderately stimulated. This indicates that xenon exerted no immunotoxic effects and can be used in patients with diseases associated with primary immunodeficiency. Study of allergic effects on albino guinea pigs showed that on days 14 and 21 of sensitization xenon in the resolving dose possessed no anaphylactogenic activity, caused no specific lysis of leukocytes, and did not modulate the counts of basophils and eosinophils. Xenon did not induce allergic reactions and is not a potential allergen, which is important in patients with panallergy.